ROSEN, LEADING INVESTOR COUNSEL, Encourages Cavco Industries, Inc. Investors to Inquire About Securities Class Action Investigation – CVCO

NEW YORK, May 20, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cavco Industries, Inc. (NASDAQ: CVCO) resulting from allegations that Cavco may have issued materially misleading business information to the investing public. SO WHAT: If you […]

NEW YORK, May 20, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cavco Industries, Inc. (NASDAQ: CVCO) resulting from allegations that Cavco may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Cavco securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=7555 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On November 8, 2018, Cavco revealed in an SEC filing that it had “received a subpoena from the SEC’s Division of Enforcement requesting certain documents relating to, among other items, trading in the stock of another public company.” On this news, Cavco share price fell $49.48 per share, or over 23%, to close at $165.20 per share on November 9, 2018.

On February 4, 2019, Cavco revealed that it had received requests for additional documents. Cavco further disclosed that it spent, and expected to spend, millions of dollars on legal and insurance expenses in relation to the SEC’s subpoenas and Cavco’s independent investigation into the matter. On this news, Cavco’s share price fell $26.92 per share, or about 16.7%, to close at $134.37 per share on February 5, 2019.

On September 2, 2021, the SEC filed a complaint against Cavco, former CEO Joseph Stegmayer, and former CFO and Chief Compliance Officer Daniel Urness. The SEC complaint alleged that Stegmayer and Urness caused Cavco to purchase shares of publicly traded companies on material non-public information. On this news, Cavco’s share price fell $6.59 per share, or about 2.5%, to close at $252.48 per share on September 3, 2021.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8843404

Previous Article

Iraqi President receives Interior Minister in Baghdad

Next Article

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Texas Capital Bancshares, Inc. Investors to Inquire About Securities Class Action Investigation – TCBI

Related Posts

ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – FENC

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”) of the important April 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased […]

‫جوي سبريدر تعلن عن نتائج غير مدققة للأرباع الثلاثة الأولى من عام 2021، مع ارتفاع الإيرادات بنسبة 61.1٪ على أساس سنوي إلى 945 مليون دولار هونج كونج

بكين، 30 نوفمبر 2021 — /PRNewswire/  في 29 نوفمبر (تشرين الثاني)، أعلنت شركة مجموعة جوي سبريدر المدرجة في بورصة هونغ كونغ تحت اسم (” Joy Spreader ” أو “الشركة”، رمز الأسهم: 06988. HK) عن نتائجها للأرباع الثلاثة الأولى من عام 2021.حققت جوي سبريدر، في الفترة من يناير إلى سبتمبر، إيرادات قدرها 945 مليون دولار هونج […]

South Asia’s largest study abroad platform Leap Scholar forays into the Middle East; appoints Zuhaib Khan as VP for International Expansion

Leap Scholar is South Asia’s largest study abroad platform with a growing community of over 1 million students The startup has appointed Zuhaib Khan as VP – International Expansion, to spearhead the company’s expansion plans globally Over the next year, the startup plans to invest over $20 million to build a world-class team in the […]

AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approval SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug […]